Health Catalyst

Health Catalyst Inc is the Salt Lake City, Utah-headquartered healthcare data-and-analytics technology firm founded in 2008 by Tom Burton, Dan Burton, Dr Steven Barlow, and a team from Intermountain Healthcare. The company sells the Ignite cloud-based data-and-analytics platform that integrates clinical, financial, and operational data across multiple disparate healthcare-software systems plus a portfolio of pre-built analytics applications targeting clinical-improvement, revenue-cycle, ambulatory-operations, and population-health use cases. The customer base is over 1,000 US hospitals and health systems including marquee accounts at Intermountain Healthcare, MultiCare Health System, Kaiser Permanente, MD Anderson, and several major academic-medical-center systems.

The 2022-to-2025 trajectory has been a steady deterioration from the post-COVID peak. Health Catalyst IPO-ed in July 2019 at 26 USD per share, peaked at 67 USD in early 2021 during the healthcare-IT optimism cycle with a market cap over 2.8 billion USD on roughly 220 million USD of annual revenue, then collapsed 98 percent to the current 1.19 USD as: (1) US hospital IT-spending budgets compressed during 2023-2025 in response to operating-margin compression from labor inflation and Medicare reimbursement cuts, (2) customer-churn accelerated as legacy health-system contracts negotiated lower renewal pricing, (3) the 2022 acquisition of ARMUS Corporation (cardiology-registry specialist) plus 2023 acquisition of Carevive (oncology-care-management) added complexity without delivering planned synergies, (4) competitive pressure from Epic Systems Cogito (now bundled free with Epic EHR) eroded share in the analytics-platform tier.

At 1.19 USD per share, Health Catalyst trades at 88 million USD market cap. Forward P/E 10.0x (implying analyst expectation of EPS recovery from current operating losses), P/Sales 0.29x (extraordinarily low for a SaaS-services healthcare-IT company), P/Book 0.64x (trading at 36 percent discount to book equity), EV/EBITDA 173x (EBITDA is barely positive but the EV is dominated by approximately 200 million USD of convertible notes from the 2020 financing round). Revenue trailing twelve months is 302 million USD, down 10.9 percent year-over-year. Gross margin is 50.4 percent (SaaS plus professional-services mix), operating margin negative 9.5 percent, profit margin negative 87.7 percent (depressed by intangible-asset write-downs from the ARMUS and Carevive acquisitions). Free cash flow is positive 24 million USD trailing twelve months — a meaningful demonstration of operational discipline despite the revenue decline.

The 52-week price range is 0.95 USD to 4.29 USD with the current 1.19 USD at 7 percent of that range — near the cycle bottom. Daily volume is approximately 1.2 million shares (1.4 million USD) — adequate liquidity for retail-scale and small-institution positions. Short interest is 16.1 percent of float — meaningfully elevated, reflecting fundamental shorts betting on continued revenue decline plus potential dilution. The investment setup is classic distressed healthcare-IT-turnaround: a real platform business with 1,000-plus customer base, positive FCF despite operating losses, trading at distressed multiples with embedded option value from operating-margin recovery, strategic-acquirer take-out (Oracle Cerner consolidation, Epic Systems vertical extension, private-equity recapitalization), or short-squeeze catalyst.

The shareholder base reflects the post-IPO history with founder-team plus institutional-growth-investor concentration. Co-founder and CEO Dan Burton directly and indirectly controls approximately 4.2 percent of shares (including Class B super-voting shares from the IPO structure). Co-founder and former CTO Tom Burton (Dan brother, departed operational role 2023 but remains on the board) holds approximately 3.1 percent. Norwest Venture Partners (the lead pre-IPO investor) retained approximately 5 percent of shares post-IPO but has gradually divested to current approximately 1.8 percent. The combined founder-plus-pre-IPO-investor ownership is approximately 9 to 10 percent.

Institutional ownership is concentrated in healthcare-technology growth funds. Notable holders include BlackRock (5.8 percent passive), Vanguard (4.2 percent passive), State Street (2.1 percent), Renaissance Technologies (1.6 percent quantitative), OrbiMed Advisors (1.4 percent healthcare-specialist), Wasatch Advisors (1.2 percent — small-cap-growth), Ameriprise (1.1 percent). Notably absent from the holder list are the typical deep-value-distressed-equity specialists (Donald Smith, Pzena, Cetus) — meaning the value-investor recognition of the distressed valuation has not yet been priced in. Combined institutional plus insider ownership is approximately 35 to 40 percent of float — concentrated enough to limit forced selling but with sufficient remaining float for active price discovery.

Insider activity in 2025 was meaningfully net-buying with conviction at multi-year lows. CEO Dan Burton purchased 200,000 shares at 1.45 USD in February 2025 (a 290,000 USD open-market buy his largest personal investment since IPO). President of Operations Patrick Nelli purchased 100,000 shares at 1.30 USD in May 2025. Board member Kevin Freeman purchased 75,000 shares at 1.10 USD in August 2025 (a 82,500 USD position-doubling buy). The cluster of insider buying at the worst quarterly pricing of the cycle is a strong conviction signal — typically indicates leadership views the current valuation as the entry point for the operating-margin recovery, not a permanent impairment.

Short interest is 16.08 percent of float (7-plus days to cover) — elevated and concentrated. The short thesis components: (1) continued revenue decline as legacy health-system contracts churn or renegotiate down, (2) Epic Cogito bundled-free competition compressing pricing power, (3) potential dilutive equity raise to support balance-sheet flexibility ahead of 2027 convertible-note maturity. Any positive operating surprise (revenue stabilization, large new contract win, strategic-transaction announcement) could trigger short-squeeze dynamics given the elevated short positioning. Daily volume of 1.2 million shares supports both flexible accumulation and the volatility necessary for short-squeeze price discovery.

At 1.19 USD Health Catalyst trades at 88 million USD market cap, 0.29x P/Sales, 0.64x P/Book, 10x forward P/E, EV/EBITDA 173x (skewed by minimal EBITDA). Enterprise value (market cap plus 200 million USD convertibles minus 75 million USD cash) is approximately 213 million USD = 0.70x EV/Sales. Three scenarios. (1) Strategic take-out at 1.5x to 2.0x revenue: 450 to 605 million USD enterprise value implies 3.50 to 5.50 USD per share, 195 to 360 percent upside over 12 to 18 months. (2) Operational stabilization plus margin recovery: 2027 revenue 290 million USD at 5 percent operating margin = 14 million USD EBIT, FCF 25 million USD, P/E 14x = 200 million USD market cap = 2.70 USD per share, 127 percent upside. (3) Continued decline plus dilutive equity raise: revenue 260 million USD, dilution doubles share count to 150 million, market cap 100 million USD = 0.65 USD per share, 45 percent downside. Analyst consensus from 6 covering brokers: William Blair 2.50 USD (Buy), Truist 2.00 USD (Buy), Canaccord 1.75 USD (Buy), Stifel 1.50 USD (Hold), Wells Fargo 1.25 USD (Hold), Morgan Stanley 1.00 USD (Hold). Mean target 1.75 USD implies 47 percent upside on consensus.

1. Q4 FY2025 earnings (March 2026):

   Q4 results plus FY2026 guidance. Revenue decline narrower than minus 5 percent plus operating-margin guidance for FY2026 better than minus 5 percent would validate the stabilization thesis and likely trigger short-squeeze given 16.08 percent short interest.

2. Convertible Note Refinancing Activity (H2 2026 to Q1 2027):

   The 200 million USD convertible notes maturing April 2027 will need refinancing approximately 12-to-15 months in advance. Successful refinancing at reasonable terms would remove the largest financial risk overhang. Failure or distressed refinancing terms would accelerate downside scenarios.

3. Strategic-Transaction Announcement (12-to-24-month horizon):

   Founder team (Dan Burton, Tom Burton plus board members) is increasingly receptive to a strategic transaction. Engagement of a financial advisor (Goldman Sachs, JP Morgan, or boutique healthcare-IT advisor like Cain Brothers) would signal active exploration. Strategic acquirers Oracle, Epic, Salesforce, plus PE firms Welsh Carson, Hellman and Friedman all have direct precedent for similar healthcare-IT take-privates.

Health Catalyst is a distressed healthcare-IT-turnaround bet with three asymmetric upside catalysts (operational stabilization, strategic take-out, short-squeeze on positive surprise) and one structural risk concentrated in the 2027 convertible-refinancing cliff. The 1,000-plus health-system customer base plus the Ignite platform stickiness provides genuine downside protection, and the founder-led insider buying at multi-year lows is a meaningful conviction signal. The positive FCF despite operating losses validates the self-funded turnaround framework.

I would size this at no more than 0.25 to 0.50 percent of portfolio with 18-month horizon and a 0.85 USD stop-loss (would invalidate the stabilization thesis). Upside scenarios cluster at 2.00 to 3.50 USD; downside floor at 0.50 to 0.85 USD set by potential refinancing scenarios. Risk-reward is approximately 3-to-1 favorable but with binary outcome distribution dominated by the 2027 convertible-refinancing resolution. Best suited for investors with explicit risk-budgeting for distressed healthcare-IT and willingness to size small. Pair with broader healthcare-tech basket (Doximity, Phreesia, Veeva) for diversification of company-specific dilution and refinancing risk.